UPDATE 2-Under pressure in diabetes, Novo Nordisk steps up focus on obesity drugs Tue, 21 Nov 2017 15:46:24 +0000 MÅLØV, Denmark, Nov 21 (Reuters) - Danish drugmaker Novo Nordisk is stepping up its efforts to treat obesity, seeking to tap into a potentially huge market as prices for its established diabetes drugs come under pressure, particularly in the United States. The world's largest maker of diabetes drugs said on Tuesday it would aim to develop medicines that treat obesity - a major cause of diabetes - at least as effectively as surgery.
Diabetes Community Awakens Important Conversation about Hidden Problem: Hypoglycemia Wed, 15 Nov 2017 16:00:00 +0000 TORONTO, Nov. 15, 2017 /CNW/ - Diabetes is one of the most challenging health problems in the 21st century. The number of people with the condition is increasing in every country worldwide, and Canada is no exception with 3.5 million people (or nearly one out of every three) living with diabetes.1 Nocturnal, or nighttime, hypoglycemia (low blood glucose levels) is a hidden problem within the diabetes community. Together, Novo Nordisk and Diabetes Canada are creating important conversations to shed light on the emotional, physical and financial impact of nighttime hypoglycemia.
Behind Sanofi’s 3Q17 Revenue Growth Tue, 14 Nov 2017 18:05:09 +0000 Sanofi (SNY) reported a growth of 4.7% in revenues at constant exchange rates to 9.05 billion euros, compared with 9.03 billion euros in 3Q16.
Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day Tue, 14 Nov 2017 14:29:02 +0000 Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
*Winners defined as our Top Picks that increased 20% or more within a 6-month period.
Red Letters imply that that particular criteria did not meet minimum requirements, e.g., a low GSA Rank would show it in red.
___ Red Line On Graph Shows a Trailing Stop Loss Based on Support and Resistance Levels. See how it works.
___ Blue Line On Graph Shows the 10-Week Moving Average.
___ Magenta Line On Graph Shows the 40-Week Moving Average.
Disclaimer The stock selections in our stock investing and stock trading database are not stock recommendations, but simply represent applications of a stock investing process. All materials, including our Top Stock Picks, are provided for information purposes only and should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security. Growth Stock Analytics, LLC is not responsible for gains/losses that may result in investing or trading in these securities. All information is believed to be obtained from reliable sources, but there is no guarantee that the information supplied is accurate, complete or timely. There is no guarantee or warranty with regard to the results obtained from its use. There is no guarantee of suitability or potential value of any particular investment or information source. You acknowledge that your requests for this information are unsolicited and shall neither constitute nor be considered investment advice. Past investing performance is not an indication of future performance results. Investing and trading in stocks is risky. Investors are encouraged to consult a registered stock broker or investment adviser before making any investing decisions. The interpretations and opinions expressed herein are solely those of Growth Stock Analytics, LLC, and not of any other individual or organization.